FDA aprueba Pimjetmi de Merck para adultos con tumor tenosinovial de células gigantes
- La FDA autorizó PIMJETMI, de Merck, para adultos con tumor tenosinovial de células gigantes sintomático cuya cirugía pueda agravar limitaciones funcionales o causar morbilidad grave.
- En el ensayo MANEUVER, la respuesta objetiva alcanzó el 56% frente al 3% con placebo a las 25 semanas.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief via Business Wire (Ref. ID: 202611101423BIZWIRE_USPR_____20261029_BW447931) on November 10, 2026, and is solely responsible for the information contained therein.